Stockscreener 앱 받기
7.67
3.76%
-0.30
시간 외 거래:
7.60
-0.07
-0.91%
전일 마감가:
$7.97
열려 있는:
$7.8
하루 거래량:
64,455
Relative Volume:
2.23
시가총액:
$12.61M
수익:
$1.47M
순이익/손실:
$-97.61M
주가수익비율:
-5.1477
EPS:
-1.49
순현금흐름:
$-80.90M
1주 성능:
+9.57%
1개월 성능:
+19.66%
6개월 성능:
+80.68%
1년 성능:
-31.12%
1일 변동 폭
$7.5052
$8.0499
1주일 범위
$6.70
$8.7478
52주 변동 폭
$3.8101
$37.50
Lyra Therapeutics Inc Stock (LYRA) Company Profile
명칭
Lyra Therapeutics Inc
전화
617-373-4600
주소
480 ARSENAL WAY, WATERTOWN, MA
LYRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
7.67 | 13.11M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-05-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-05-06 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 재개 | BTIG Research | Buy |
| 2023-08-31 | 개시 | H.C. Wainwright | Buy |
| 2022-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 개시 | BTIG Research | Buy |
| 2020-05-26 | 개시 | BofA/Merrill | Buy |
| 2020-05-26 | 개시 | Jefferies | Buy |
| 2020-05-26 | 개시 | William Blair | Outperform |
모두보기
Lyra Therapeutics Inc 주식(LYRA)의 최신 뉴스
Regression analysis insights on Lyra Therapeutics Inc. performanceWeekly Market Report & Safe Capital Growth Tips - newser.com
Using data models to predict Lyra Therapeutics Inc. stock movement2025 Technical Overview & Fast Momentum Entry Tips - newser.com
Published on: 2025-10-09 05:19:19 - newser.com
Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate - Stocktwits
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Lyra Therapeutics outlines path to NDA for CRS treatment - Investing.com
Lyra Therapeutics (LYRA) Advances CRS Treatment with Positive Tr - GuruFocus
Lyra Therapeutics outlines path to NDA for CRS treatment By Investing.com - Investing.com Australia
Lyra unveils clinical plan for LYR-210, to present late-stage sinusitis trial data - MarketScreener
Lyra Therapeutics Announces Clinical Plan for LYR-210 Following Positive ENLIGHTEN 2 Results and Upcoming FDA Engagement - Quiver Quantitative
Lyra Therapeutics, Inc. Announces Clinical Plan for Lyr-210 and Late-Breaking Oral Presentation of Phase 3 Enlighten 2 Study - MarketScreener
Multi asset correlation models including Lyra Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
What the charts say about Lyra Therapeutics Inc. todayJuly 2025 Selloffs & Intraday High Probability Setup Alerts - newser.com
Using Python tools to backtest Lyra Therapeutics Inc. strategiesMarket Volume Summary & Real-Time Volume Triggers - newser.com
Is Lyra Therapeutics Inc. stock supported by strong cash flowsLayoff News & Free Weekly Chart Analysis and Trade Guides - newser.com
What analysts say about Lyra Therapeutics Inc stockRisk Adjusted Returns & Free Stock Price Trend Analysis - earlytimes.in
Is Lyra Therapeutics Inc. stock ready for a breakoutPrice Action & Growth Focused Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 185,314 Shares of Lyra Therapeutics, Inc. $LYRA - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Price Up 0.5% – Here’s Why - Defense World
Is Lyra Therapeutics Inc a good long term investmentUtilities Sector Analysis & Target Triple-Digit Stock Opportunities - earlytimes.in
What drives Lyra Therapeutics Inc stock priceEarnings Miss Alerts & Capital Allocation Recommendations - earlytimes.in
US Market Recap: How much upside does Lyra Therapeutics Inc haveGDP Growth & Trade Opportunity Analysis - خودرو بانک
Tech Rally: Is Lyra Therapeutics Inc stock a good pick for beginnersMarket Performance Report & Verified Technical Signals - khodrobank.com
Quantitative breakdown of Lyra Therapeutics Inc. recent moveJuly 2025 Closing Moves & High Accuracy Swing Entry Alerts - newser.com
Market Moves: Should I hold or sell Lyra Therapeutics Inc nowEarnings Summary Report & Low Risk High Reward Trade Ideas - خودرو بانک
Live market analysis of Lyra Therapeutics Inc.July 2025 Earnings & Risk Adjusted Buy and Sell Alerts - newser.com
Top chart patterns to watch in Lyra Therapeutics Inc.IPO Watch & Safe Capital Growth Trade Ideas - newser.com
Can swing trading help recover from Lyra Therapeutics Inc. lossesBull Run & Technical Entry and Exit Alerts - newser.com
Is Lyra Therapeutics Inc. a candidate for recovery playJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
Travel Stocks: Will Lyra Therapeutics Inc. face regulatory challenges2025 Volume Leaders & Fast Exit and Entry Strategy Plans - خودرو بانک
Macro Review: Why is AGNCL stock going up2025 Dividend Review & Fast Gain Swing Alerts - خودرو بانک
Trading Recap: Can Lyra Therapeutics Inc outperform under higher oil prices2025 Buyback Activity & Safe Capital Investment Plans - خودرو بانک
Weekly Earnings: Should I trade or invest in Koninklijke Philips N.V. Depositary ReceiptJuly 2025 Spike Watch & Reliable Breakout Forecasts - خودرو بانک
Sectors Review: Can Lyra Therapeutics Inc outperform under higher oil pricesMarket Volume Summary & Consistent Income Trade Recommendations - خودرو بانک
ETF Watch: Can Kennametal Inc. lead its sector in growthTrade Volume Summary & Daily Entry Point Alerts - خودرو بانک
Lyra Therapeutics Inc (LYRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lyra Therapeutics Inc 주식 (LYRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Cavalier Jason | Chief Financial Officer |
Jul 10 '25 |
Sale |
8.91 |
684 |
6,094 |
519,316 |
5.74%
자본화:
|
볼륨(24시간):